Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease.
Identifieur interne : 001049 ( PubMed/Checkpoint ); précédent : 001048; suivant : 001050Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease.
Auteurs : Ivan L. Cepeda [Canada] ; Joseph Flores ; Michael L. Cornfeldt ; John R. O'Kusky ; Doris J. DoudetSource :
- Journal of neuropathology and experimental neurology [ 0022-3069 ] ; 2007.
English descriptors
- KwdEn :
- Analysis of Variance, Animals, Autoradiography, Cell Transplantation (methods), Cocaine (analogs & derivatives), Cocaine (pharmacokinetics), Corpus Striatum (drug effects), Disease Models, Animal, Dopamine Uptake Inhibitors (pharmacokinetics), Extremities (physiopathology), Functional Laterality, Humans, Male, Motor Neuron Disease (etiology), Motor Neuron Disease (pathology), Motor Neuron Disease (surgery), Parkinson Disease (complications), Parkinson Disease (etiology), Parkinson Disease (surgery), Pigment Epithelium of Eye (transplantation), Psychomotor Performance (physiology), Rats, Rats, Sprague-Dawley, Time Factors, Transplantation, Heterologous (methods).
- MESH :
- chemical , analogs & derivatives : Cocaine.
- complications : Parkinson Disease.
- drug effects : Corpus Striatum.
- etiology : Motor Neuron Disease, Parkinson Disease.
- methods : Cell Transplantation, Transplantation, Heterologous.
- pathology : Motor Neuron Disease.
- chemical , pharmacokinetics : Cocaine, Dopamine Uptake Inhibitors.
- physiology : Psychomotor Performance.
- physiopathology : Extremities.
- surgery : Motor Neuron Disease, Parkinson Disease.
- transplantation : Pigment Epithelium of Eye.
- Analysis of Variance, Animals, Autoradiography, Disease Models, Animal, Functional Laterality, Humans, Male, Rats, Rats, Sprague-Dawley, Time Factors.
Abstract
Intrastriatal transplantation of gelatin microcarrier-attached human retinal pigment epithelial cells (hRPE-GM) may represent an alternative source for cell therapy in Parkinson disease (PD). The use of human retinal pigment epithelial (hRPE) cells in PD relies on the capacity of these cells to produce l-dopa as an intermediate product in the eumelanin synthesis pathway. We investigated the behavioral effects of hRPE-GM implants on forelimb use asymmetries and hindlimb motor deficits in unilateral and bilateral 6-hydroxydopamine (6-OHDA) rat models of PD. We report that intrastriatal unilateral implantation of hRPE-GM in rats with 6-OHDA nigrostriatal lesions produce an amelioration of the contralateral forelimb disuse and the contralateral hindlimb deficits. These results further support the possibility that implantation of cultured hRPE cells may be a promising therapeutic option for patients with PD.
DOI: 10.1097/nen.0b013e318093e521
PubMed: 17620983
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:17620983Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease.</title><author><name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L" last="Cepeda">Ivan L. Cepeda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name></author><author><name sortKey="Cornfeldt, Michael L" sort="Cornfeldt, Michael L" uniqKey="Cornfeldt M" first="Michael L" last="Cornfeldt">Michael L. Cornfeldt</name></author><author><name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R" last="O'Kusky">John R. O'Kusky</name></author><author><name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J" last="Doudet">Doris J. Doudet</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17620983</idno><idno type="pmid">17620983</idno><idno type="doi">10.1097/nen.0b013e318093e521</idno><idno type="wicri:Area/PubMed/Corpus">001060</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001060</idno><idno type="wicri:Area/PubMed/Curation">001060</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001060</idno><idno type="wicri:Area/PubMed/Checkpoint">001060</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001060</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease.</title><author><name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L" last="Cepeda">Ivan L. Cepeda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name></author><author><name sortKey="Cornfeldt, Michael L" sort="Cornfeldt, Michael L" uniqKey="Cornfeldt M" first="Michael L" last="Cornfeldt">Michael L. Cornfeldt</name></author><author><name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R" last="O'Kusky">John R. O'Kusky</name></author><author><name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J" last="Doudet">Doris J. Doudet</name></author></analytic><series><title level="j">Journal of neuropathology and experimental neurology</title><idno type="ISSN">0022-3069</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Autoradiography</term><term>Cell Transplantation (methods)</term><term>Cocaine (analogs & derivatives)</term><term>Cocaine (pharmacokinetics)</term><term>Corpus Striatum (drug effects)</term><term>Disease Models, Animal</term><term>Dopamine Uptake Inhibitors (pharmacokinetics)</term><term>Extremities (physiopathology)</term><term>Functional Laterality</term><term>Humans</term><term>Male</term><term>Motor Neuron Disease (etiology)</term><term>Motor Neuron Disease (pathology)</term><term>Motor Neuron Disease (surgery)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (etiology)</term><term>Parkinson Disease (surgery)</term><term>Pigment Epithelium of Eye (transplantation)</term><term>Psychomotor Performance (physiology)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Time Factors</term><term>Transplantation, Heterologous (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Motor Neuron Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell Transplantation</term><term>Transplantation, Heterologous</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Motor Neuron Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Cocaine</term><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Extremities</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Motor Neuron Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Pigment Epithelium of Eye</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Autoradiography</term><term>Disease Models, Animal</term><term>Functional Laterality</term><term>Humans</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intrastriatal transplantation of gelatin microcarrier-attached human retinal pigment epithelial cells (hRPE-GM) may represent an alternative source for cell therapy in Parkinson disease (PD). The use of human retinal pigment epithelial (hRPE) cells in PD relies on the capacity of these cells to produce l-dopa as an intermediate product in the eumelanin synthesis pathway. We investigated the behavioral effects of hRPE-GM implants on forelimb use asymmetries and hindlimb motor deficits in unilateral and bilateral 6-hydroxydopamine (6-OHDA) rat models of PD. We report that intrastriatal unilateral implantation of hRPE-GM in rats with 6-OHDA nigrostriatal lesions produce an amelioration of the contralateral forelimb disuse and the contralateral hindlimb deficits. These results further support the possibility that implantation of cultured hRPE cells may be a promising therapeutic option for patients with PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17620983</PMID><DateCreated><Year>2007</Year><Month>07</Month><Day>10</Day></DateCreated><DateCompleted><Year>2007</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3069</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J. Neuropathol. Exp. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>576-84</MedlinePgn></Pagination><Abstract><AbstractText>Intrastriatal transplantation of gelatin microcarrier-attached human retinal pigment epithelial cells (hRPE-GM) may represent an alternative source for cell therapy in Parkinson disease (PD). The use of human retinal pigment epithelial (hRPE) cells in PD relies on the capacity of these cells to produce l-dopa as an intermediate product in the eumelanin synthesis pathway. We investigated the behavioral effects of hRPE-GM implants on forelimb use asymmetries and hindlimb motor deficits in unilateral and bilateral 6-hydroxydopamine (6-OHDA) rat models of PD. We report that intrastriatal unilateral implantation of hRPE-GM in rats with 6-OHDA nigrostriatal lesions produce an amelioration of the contralateral forelimb disuse and the contralateral hindlimb deficits. These results further support the possibility that implantation of cultured hRPE cells may be a promising therapeutic option for patients with PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cepeda</LastName><ForeName>Ivan L</ForeName><Initials>IL</Initials><AffiliationInfo><Affiliation>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cornfeldt</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>O'Kusky</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Doudet</LastName><ForeName>Doris J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>50370-56-4</RegistryNumber><NameOfSubstance UI="C021279">(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001345" MajorTopicYN="N">Autoradiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017690" MajorTopicYN="N">Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003042" MajorTopicYN="N">Cocaine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018765" MajorTopicYN="N">Dopamine Uptake Inhibitors</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005121" MajorTopicYN="N">Extremities</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010857" MajorTopicYN="N">Pigment Epithelium of Eye</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17620983</ArticleId><ArticleId IdType="doi">10.1097/nen.0b013e318093e521</ArticleId><ArticleId IdType="pii">00005072-200707000-00003</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Cornfeldt, Michael L" sort="Cornfeldt, Michael L" uniqKey="Cornfeldt M" first="Michael L" last="Cornfeldt">Michael L. Cornfeldt</name><name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J" last="Doudet">Doris J. Doudet</name><name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name><name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R" last="O'Kusky">John R. O'Kusky</name></noCountry><country name="Canada"><noRegion><name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L" last="Cepeda">Ivan L. Cepeda</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001049 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001049 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:17620983
|texte= Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:17620983" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |